Oppenheimer Raises Price Target for Humana (NYSE: HUM) Amid Strong Medicare Advantage Performance

Oppenheimer upgraded Humana's price target to $475.00 from $405.00, maintaining an 'Outperform' rating.
The new target implies 22.70% potential stock upside from Humana's current trading price of $387.12.
Humana (NYSE: HUM)'s strong Medicare Advantage star ratings, with 95% of members in four-star plans, drove a 15% premarket share rise.

Humana (NYSE: HUM) is a prominent health insurer with a large Medicare Advantage business. Oppenheimer maintains its 'Outperform' rating on Humana and raises its price target to $475.00 from $405.00. An 'Outperform' rating means the firm expects the stock to do better than the broader market.
Currently, Humana trades at $387.12 when the update is posted. Oppenheimer’s new target price is $87.88 above that price, implying about 22.70% potential stock upside. A price target is an analyst’s estimate, not a guaranteed future share price.
Humana says 95% of its Medicare Advantage members are in plans rated at least four stars for 2027. Higher star ratings can make more members eligible for quality-related bonus payments.